Method and kit for treating lower bowel pain

• US 20040142968A1
• Filed: 01/17/2003
• Published: 07/22/2004
• Est. Priority Date: 01/17/2003
• Status: Abandoned Application

• Current Assignee: Geno-Mechanix, LLC
• Original Assignee: Geno-Mechanix, LLC
• Inventors: Price, Donald, Verne, G. Nicholas, Sen, Arup
• Application Number:
  US10/347,048
• Publication Number:
  US 20040142968A1
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/02 Suppositories; Bougies; Bases therefor; Ovulesapparatus for making A61J3/08; devices for introducing into the body A61M31/00

Abstract

Lower bowel pain such as that associated with menses, premenstrual syndrome (PMS) or irritable bowel syndrome is alleviated in a mammal suffering therefrom by administering to the mammal a pain alleviating amount of nontoxic local anesthetic such as lidocaine, lidocaine hydrochloride, bupivicaine, and the like. These local anesthetics will be applied as an injected intra rectal jelly, intra rectal suppository, or orally in capsule form.

Claims

1. A method of reducing pain that arises from nerve impulses from the colon or rectum and is associated with a condition selected from the group consisting of menses, premenstrual syndrome, irritable bowel syndrome, anal fissures, internal/external hemorrhoids, rectal prolapse, proctalgia fugax, levator ani syndrome, and pudendal canal syndrome that comprises administering in the colon of a mammal exhibiting pain associated with irritable bowel syndrome, anal fissures, internal/external hemorrhoids, rectal prolapse, proctalgia fugax, levator ani syndrome, and pudendal canal syndrome by the application of a pain-alleviating amount of at least one non-toxic local anesthetic selected from the group consisting of lidocaine, lidocaine hydrochoride, bupivicaine hydrochloride, levobupivicaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxyamide), chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, mepivicaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride, tetracaine, and tetracaine hydrochloride.

2. The method of claim 1 wherein the nontoxic local anesthetic is provided as an intrarectal suppository with 2% lidocaine jelly as the principle ingredient.

3. The method of claim 1 wherein the nontoxic local anesthetic is provided as an intrarectal jelly administered by a plastic syringe or plastic rectal tube.

4. The method of claim 1 wherein the nontoxic local anesthetic is provided by intrarectal sustained release capsules.

5. The method of claim 1 wherein the nontoxic local anesthetic is provided by oral administration and is selectively released in the colon.

6. The method of claim 1 wherein the nontoxic local anesthetic is provided by oral sustained release capsules that dissolve at a pH<

6.0 and is selectively released in the colon.

7. The method of claim 1 wherein the dose is polyacrylate free.

8. A method of treating pain associated with pre-menses or menses that comprises administering in the rectum, colon or vagina of a human female exhibiting pain associated with menses or pre-menses a pain-alleviating amount of at least one non-toxic local anesthetic.

9. The method of claim 8 wherein the non-toxic local anesthetic is selected from the group consisting of lidocaine, lidocaine hydrochoride, bupivicaine hydrochloride, levobupivicaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxyamide), chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, mepivicaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride, tetracaine, and tetracaine hydrochloride.

10. The method of claims 8 wherein the nontoxic local anesthetic is provided as an intra-rectal or vaginal suppository with 2% lidocaine jelly as the principle ingredient.

11. The method of claim 8 wherein the nontoxic local anesthetic is provided as an intra-rectal or vaginal jelly administered by a plastic syringe or plastic rectal tube

12. The method of claim 8 wherein the nontoxic local anesthetic is provided by intra rectal sustained release capsules.

13. The method of claim 8 wherein the nontoxic local anesthetic is provided by oral administration and is selectively released in the colon.

14. The method of claim 8 wherein the nontoxic local anesthetic is provided by oral sustained release capsules that dissolve at a pH<

6.0 and is selectively released in the colon

15. A kit for treating lower bowel pain that comprises an applicator, a dose of a local anesthetic selected from the group consisting of lidocaine, lidocaine hydrochoride, bupivicaine hydrochloride, levobupivicaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxyamide), chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, mepivicaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride, tetracaine, and tetracaine hydrochloride and an instruction sheet describing a treatment for pain associated with a condition selected from the group consisting of menses, premenstrual syndrome, irritable bowel syndrome, anal fissures, internal/external hemorrhoids, rectal prolapse, proctalgia fugax, levator ani syndrome, and pudendal canal syndrome.

16. The kit of claim 15 wherein the dose comprises 2% lidocaine jelly as the principle ingredient.

17. The kit of claim 15 wherein the dose is provided in a sustained release form.

18. A method of treating lower bowel pain that comprises administering in the rectum or colon of a human exhibiting pain associated with irritable bowel syndrome a pain-alleviating amount of at least one non-toxic local anesthetic selected from the group consisting of lidocaine, lidocaine hydrochoride, bupivicaine hydrochloride, levobupivicaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxyamide), chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, mepivicaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride, tetracaine, and tetracaine hydrochloride.

19. The method of claim 18 wherein the nontoxic local anesthetic is provided as an intra-rectal suppository with 2% lidocaine jelly as the principle ingredient.

20. The method of claim 18 wherein the nontoxic local anesthetic is provided as an intra-rectal jelly administered by a plastic syringe or plastic rectal tube

21. The method of claim 18 wherein the nontoxic local anesthetic is provided by intra rectal sustained release capsules.

22. The method of claim 18 wherein the nontoxic local anesthetic is provided by oral administration and is selectively released in the colon

23. The method of claim 18 wherein the nontoxic local anesthetic is provided by oral sustained release capsules that dissolve at a pH<

6.0 and is selectively released in the colon

24. A method of reducing pain that arises from nerve impulses from the colon or rectum and is associated with a chronic condition that comprises administering in the colon of a mammal exhibiting lower bowel pain a pain-alleviating amount of at least one non-toxic local anesthetic selected from the group consisting of lidocaine, lidocaine hydrochoride, bupivicaine hydrochloride, levobupivicaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxyamide), chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, mepivicaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride, tetracaine, and tetracaine hydrochloride.

25. The method of claim 24 wherein the nontoxic local anesthetic is provided as an intra-rectal suppository with 2% lidocaine jelly as the principle ingredient.

26. The method of claim 24 wherein the nontoxic local anesthetic is provided as an intra-rectal jelly administered by a plastic syringe or plastic rectal tube

27. The method of claim 24 wherein the nontoxic local anesthetic is provided by intra rectal sustained release capsules.

28. The method of claim 24 wherein the nontoxic local anesthetic is provided by oral administration and is selectively released in the colon

29. The method of claim 24 wherein the nontoxic local anesthetic is provided by oral sustained release capsules that dissolve at a pH<

6.0 and is selectively released in the colon

30. A method of reducing pain that arises from nerve impulses from the colon or rectum and is associated with a chronic condition that comprises administering in the colon of a mammal exhibiting tonic nerve input-caused lower bowel pain a pain-alleviating amount of at least one non-toxic polyacrylate free local anesthetic.

31. The method of claim 30 wherein the nontoxic local anesthetic is provided as an intra-rectal suppository with 2% lidocaine jelly as the principle ingredient.

32. The method of claim 30 wherein the nontoxic local anesthetic is provided as an intra-rectal jelly administered by a plastic syringe or plastic rectal tube

33. The method of claim 30 wherein the nontoxic local anesthetic is provided by intra rectal sustained release capsules.

34. The method of claim 30 wherein the nontoxic local anesthetic is provided by oral administration and is selectively released in the colon

35. The method of claim 30 wherein the nontoxic local anesthetic is provided by oral sustained release capsules that dissolve at a pH<

6.0 and is selectively released in the colon